The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
CTEP 9557: A dose-escalation trial of combination dabrafenib, trametinib, and AT13387 in patients with BRAF mutant solid tumors.
 
Meghan Mooradian
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca
 
James M. Cleary
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Merck; Tesaro
Travel, Accommodations, Expenses - Agios; Bristol-Myers Squibb; Roche
 
Justine Vanessa Cohen
Consulting or Advisory Role - Bristol-Myers Squibb; Genzyme
 
Donald P. Lawrence
No Relationships to Disclose
 
Elizabeth Iannotti Buchbinder
Employment - Alexion Pharmaceuticals (I); Biodesix (I); Sanofi (I)
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Novartis
Research Funding - Bristol-Myers Squibb; Checkmate Pharmaceuticals; Lilly; Merck; Novartis
 
Anita Giobbie-Hurder
No Relationships to Disclose
 
Aparna Raj Parikh
Consulting or Advisory Role - Driver, Inc; Foundation Medicine; Lilly; Natera; PureTech
Research Funding - Array BioPharma (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Guardant Health (Inst); Lilly (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Plexxikon (Inst); Tesaro (Inst); Tolero Pharmaceuticals (Inst)
 
Geoffrey Shapiro
Consulting or Advisory Role - Almac Diagnostics; Angiex; Artios; Astex Pharmaceuticals; Atrin Pharmaceuticals; Bayer; Bicycle Therapeutics; Boehringer Ingelheim; Boehringer Ingelheim; Concarlo; Cybrexa Therapeutics; Daiichi Sankyo; Fusion Pharmaceuticals; G1 Therapeutics; Ipsen; Lilly; Merck Serono; Pfizer; Roche; Seagen; Sierra Oncology
Research Funding - Aileron Therapeutics (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CanBas (Inst); Cellceutix (Inst); Clovis Oncology (Inst); Covidien (Inst); Curis (Inst); Cyclacel (Inst); Esperas Pharma (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immune Design (Inst); Lilly (Inst); Merck (Inst); Merck Serono (Inst); Millennium (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); PTC Therapeutics (Inst); Puma Biotechnology (Inst); Roche (Inst); Sanofi (Inst); Seagen (Inst); Sierra Oncology (Inst); Syros Pharmaceuticals (Inst); Tensha Therapeutics (Inst); Tesaro (Inst); Vertex (Inst)
Patents, Royalties, Other Intellectual Property - Patent #: 9872874 Title: Dosage regimen for sapacitabine and seliciclib Issue Date: 1/23/2018; Provisional Patent #:62/538,319 Title: Compositions and methods for predicting response and resistance to CDK4/6 inhibition Filed: 7/28/17
Travel, Accommodations, Expenses - Bayer; Bicycle Therapeutics; G1 Therapeutics; Lilly; Pfizer; Sierra Oncology
 
Lancia Darville
No Relationships to Disclose
 
Keiran Smalley
Honoraria - Elsevier
 
John M Koomen
No Relationships to Disclose
 
Amber Newton
No Relationships to Disclose
 
Harold N. Keer
Employment - Astex Pharmaceuticals
 
S. Percy Ivy
No Relationships to Disclose
 
Helen X. Chen
No Relationships to Disclose
 
Ryan J. Sullivan
Consulting or Advisory Role - ACI Clinical; Array BioPharma; Asana Biosciences; Merck; Novartis; Replimune; Syndax; WorldCare Clinical, LLC
Research Funding - Aeglea Biotherapeutics (Inst); Amgen (Inst); Asana Biosciences (Inst); BioMed Valley Discoveries (Inst); Compugen (Inst); Deciphera (Inst); Lilly (Inst); Merck (Inst); Moderna Therapeutics (Inst); Neon Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Viralytics (Inst)
Other Relationship - Boehringer Ingelheim